Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Net Cash Flow: 2009-2024

Historic Net Cash Flow for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Dec 2024 value amounting to -$3.6 million.

  • Ironwood Pharmaceuticals' Net Cash Flow rose 375.24% to $47.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.9 million, marking a year-over-year increase of 328.34%. This contributed to the annual value of -$3.6 million for FY2024, which is 99.37% up from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported Net Cash Flow of -$3.6 million as of FY2024, which was up 99.37% from -$565.7 million recorded in FY2023.
  • Over the past 5 years, Ironwood Pharmaceuticals' Net Cash Flow peaked at $257.1 million during FY2021, and registered a low of -$565.7 million during FY2023.
  • In the last 3 years, Ironwood Pharmaceuticals' Net Cash Flow had a median value of -$3.6 million in 2024 and averaged -$177.7 million.
  • In the last 5 years, Ironwood Pharmaceuticals' Net Cash Flow skyrocketed by 11,667.33% in 2020 and then crashed by 1,668.25% in 2023.
  • Over the past 5 years, Ironwood Pharmaceuticals' Net Cash Flow (Yearly) stood at $185.5 million in 2020, then spiked by 38.56% to $257.1 million in 2021, then crashed by 85.97% to $36.1 million in 2022, then slumped by 1,668.25% to -$565.7 million in 2023, then surged by 99.37% to -$3.6 million in 2024.